Skip to main content

Advertisement

Log in

Cardiovascular Risk Reduction via Increasing HDL Cholesterol: The Promise of the dal-OUTCOMES Trial

  • Clinical Trial Report
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1991;7:7S.

    Google Scholar 

  2. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256(20):2835–2838.

    Article  CAS  PubMed  Google Scholar 

  3. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.

    CAS  PubMed  Google Scholar 

  4. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased highdensity lipoproteins. Nature 1989;342:448–51.

    Article  CAS  PubMed  Google Scholar 

  5. Barter PJ, Nicholls S, Rye KA, et al.; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109–22.

    Article  CAS  PubMed  Google Scholar 

  6. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465–1473.

    Article  CAS  PubMed  Google Scholar 

  7. Stein EA, Stroes ESG, Steiner G, et al. Safety and tolerability of dalcetrapib. AmJ Cardiol 2009;104:82–91.

    Article  CAS  Google Scholar 

  8. Van Der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634–642.

    Article  PubMed  Google Scholar 

  9. Ansell BJ, Fonarow GC, Fogelman AM. Highdensity lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 2006;8(5):405–411.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of interest: K. Soe: none; A. Alam: is the Research Associate for the dal-OUTCOMES trial at SUNY-Downstate, Brooklyn, NY; C. Philip: none; E. Ruiz: none; K. Ramkissoon: none; S.I. McFarlane: is the site Principal Investigator at SUNY-Downstate, Brooklyn, NY.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Samy I. McFarlane.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soe, K., Alam, A., Philip, C. et al. Cardiovascular Risk Reduction via Increasing HDL Cholesterol: The Promise of the dal-OUTCOMES Trial. Curr Diab Rep 11, 4–6 (2011). https://doi.org/10.1007/s11892-010-0165-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-010-0165-8

Keywords

Navigation